Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracellular tacrolimus pharmacokinetics in CD3+ T lymphocytes after kidney transplantation
NL-OMON51867Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- May 2022
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tacrolimus in Kidney allograft status (RTx), sponsored by Erasmus MC. Primary endpoints: Intracellular tacrolimus concentration in CD3+ T lymphocytes and Population pharmacokinetic model of tacrolimus. Started May 2022; status: active, not recruiting.
02
Drugs
tacrolimus
03
Conditions
Kidney allograft status (RTx)
Beyond the preview
Go deeper on NL-OMON51867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51867.